Serum anti-heart and anti-intercalated disk autoantibodies provide novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis (P=0.04).
Observational (n=270)
Sí
Do serum AHAs and AIDAs serve as diagnostic autoimmune markers in patients with cardiac sarcoidosis?
Serum AHAs and AIDAs may serve as novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis.
valor p: p=0.04
BACKGROUND: Sarcoidosis is an immune-mediated disease. Cardiac involvement, a granulomatous form of myocarditis, is under-recognized and prognostically relevant. Anti-heart autoantibodies (AHAs) and anti-intercalated disk autoantibodies (AIDAs) are autoimmune markers in nonsarcoidosis myocarditis forms. OBJECTIVE: The aim was to assess serum AHAs and AIDAs as autoimmune markers in cardiac sarcoidosis. METHODS: = 270). Sarcoidosis patients were recruited in two recruiting tertiary centers in the USA and Italy. AHAs and AIDAs were detected by indirect immunofluorescence on the human myocardium and skeletal muscle. RESULTS: = 0.04). CONCLUSIONS: Serum AHAs and AIDAs provide novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis.
Caforio et al. (Wed,) conducted a observational in Cardiac sarcoidosis (n=270). Serum AHAs and AIDAs assessment was evaluated on Serum AHAs and AIDAs as autoimmune markers (p=0.04). Serum anti-heart and anti-intercalated disk autoantibodies provide novel noninvasive diagnostic autoimmune markers for cardiac sarcoidosis (P=0.04).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: